Open Access

Tanshinone IIA and Astragaloside IV promote the angiogenesis of mesenchymal stem cell-derived endothelial cell-like cells via upregulation of Cx37, Cx40 and Cx43

  • Authors:
    • Zhe Li
    • Sha Zhang
    • Liang Cao
    • Wei Li
    • Yu‑Chen Ye
    • Zi‑Xuan Shi
    • Zong‑Ren Wang
    • Lian‑Xu Sun
    • Jia‑Wei Wang
    • Lin‑Tao Jia
    • Wen Wang
  • View Affiliations

  • Published online on: December 15, 2017     https://doi.org/10.3892/etm.2017.5636
  • Pages: 1847-1854
  • Copyright: © Li et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: HTML 0 views | PDF 0 views     Cited By (CrossRef): 0 citations

Abstract

Tanshinone IIA (Tan IIA) and Astragaloside IV (AGS‑IV) were used as therapeutic treatments for coronary heart diseases (CHDs) in ancient China. However, the underlying mechanisms mediating the effects of Tan IIA and AGS‑IV in angiogenesis remain unknown. In the present study, mesenchymal stem cells (MSCs) were induced to differentiate into endothelial cell (EC)‑like cells in vitro and the effects of Tan IIA and/or AGS‑IV on the functions of these cells, including cell proliferation and tube formation, were assessed. Compared with the single‑agent groups (Tan IIA or AGS‑IV only), combined‑agent (Tan IIA and AGS‑IV) treatment significantly enhanced the proliferation and tube formation capacity of EC‑like cells. In addition, the expression of connexin 37 (Cx37), Cx40 and Cx43 in the combined‑agent group was significantly increased compared with the single‑agent groups. Furthermore, enhanced gap junctional intercellular communication (GJIC) was identified in the combined‑agent group, as evidenced by increased dye transfer in scrape‑loading dye transfer assays. In conclusion, Tan IIA and AGS‑IV may promote the angiogenesis of EC‑like cells by upregulating the expression of Cx37, Cx40 and Cx43 and enhancing GJIC function. The results of the present study may provide experimental evidence for the clinical application of Tan IIA and AGS‑IV as a treatment for CHDs.

Related Articles

Journal Cover

February 2018
Volume 15 Issue 2

Print ISSN: 1792-0981
Online ISSN:1792-1015

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Li, Z., Zhang, S., Cao, L., Li, W., Ye, Y., Shi, Z. ... Wang, W. (2018). Tanshinone IIA and Astragaloside IV promote the angiogenesis of mesenchymal stem cell-derived endothelial cell-like cells via upregulation of Cx37, Cx40 and Cx43. Experimental and Therapeutic Medicine, 15, 1847-1854. https://doi.org/10.3892/etm.2017.5636
MLA
Li, Z., Zhang, S., Cao, L., Li, W., Ye, Y., Shi, Z., Wang, Z., Sun, L., Wang, J., Jia, L., Wang, W."Tanshinone IIA and Astragaloside IV promote the angiogenesis of mesenchymal stem cell-derived endothelial cell-like cells via upregulation of Cx37, Cx40 and Cx43". Experimental and Therapeutic Medicine 15.2 (2018): 1847-1854.
Chicago
Li, Z., Zhang, S., Cao, L., Li, W., Ye, Y., Shi, Z., Wang, Z., Sun, L., Wang, J., Jia, L., Wang, W."Tanshinone IIA and Astragaloside IV promote the angiogenesis of mesenchymal stem cell-derived endothelial cell-like cells via upregulation of Cx37, Cx40 and Cx43". Experimental and Therapeutic Medicine 15, no. 2 (2018): 1847-1854. https://doi.org/10.3892/etm.2017.5636